"Golden Rule" PRRS Control - Dr. Dale Polson, at the Boehringer Ingelheim Vetmedica, Inc. Swine Health Seminar, August 15, 2009, Carolina Beach, North Carolina, USA.
Protocolo bioseguridad en porcinos ufpsoyeyisernaj
Este documento presenta el protocolo de bioseguridad para un proyecto porcino ubicado en el municipio de Ocaña, Norte de Santander. Describe las medidas de bioseguridad requeridas por el ICA como registro de entrada y salida, limpieza y desinfección, control de plagas, tratamiento de agua y residuos. También incluye un diagnóstico del proyecto, identificando sus fortalezas como ducha, lavado de botas y registros de control, y áreas que requieren mejora.
Dr. Cameron Schmitt - Talking Animal Health - PRRS: The Challenge ContinuesJohn Blue
Talking Animal Health - PRRS: The Challenge Continues - Dr. Cameron Schmitt, Pipestone Vet Clinic, from the 2013 Iowa Pork Congress, January 23-24, Des Moines, IA, USA.
More presentations at http://www.swinecast.com/2013-iowa-pork-congress
This document discusses Porcine Reproductive and Respiratory Syndrome (PRRS), including its epidemiology, vaccination strategies, and control. It begins with an outline of the presentation topics, which include the disease profile, diagnostic protocol, and prevention/control strategies. It then discusses the typical and atypical forms of PRRS, describing symptoms, transmission patterns, and field observations. The document recommends vaccination programs for naive, stable positive, and unstable positive herds. It emphasizes that vaccination, close herd management, biosecurity programs, and best management practices are required to control PRRS.
Dr. Andres Perez - PRRS Epidemiology: Best Principles of Control at a Regiona...John Blue
PRRS Epidemiology: Best Principles of Control at a Regional Level - Dr. Andres Perez, University of Minnesota, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Dr. Julie Menard - What Would Dr. Leman Do... for PRRSJohn Blue
What Would Dr. Leman Do... for PRRS - Dr. Julie Menard, F. Menard, Inc., from the 2012 Allen D. Leman Swine Conference, September 15-18, St. Paul, Minnesota, USA.
Dr. David Wright - PRRS: Understanding the Current State, Future Impact and W...John Blue
The document discusses the current situation of PRRS (Porcine Reproductive and Respiratory Syndrome) in Minnesota and nationally. It provides an update on the progress of the Minnesota N212 Regional PRRS Elimination Project, including a decrease in positive sites. Additional research findings are presented on monitoring during herd closure, impacts of PRRS vaccination methods, and transport biosecurity. Opportunities for further progress in 2014 include expanding to include PEDV and automating data collection. Continued cooperation and communication are needed to control and eliminate PRRS.
Dr. Kurt Rossow - Disease Mapping for PRRSJohn Blue
Disease Mapping for PRRS - Dr. Kurt Rossow, DVM, Veterinary Diagnostic Laboratory, University of Minnesota, from the 2013 Minnesota Pork Congress, January 16-17, Minneapolis, MN, USA.
More presentations at http://www.swinecast.com/2013-minnesota-pork-congress
This document discusses strategies for controlling PRRS (Porcine Reproductive and Respiratory Syndrome) and Aujesky's disease in swine. It emphasizes that biosecurity, control measures, and eradication efforts are needed to manage these prevalent and costly diseases. Specifically, it highlights that biosecurity is critical to prevent virus transmission between farms, control aims to minimize damage from the virus, and eradication seeks to ultimately remove the virus. It also contrasts key differences between PRRS and Aujesky's viruses and discusses vaccination and testing strategies used for eradication of Aujesky's disease.
Protocolo bioseguridad en porcinos ufpsoyeyisernaj
Este documento presenta el protocolo de bioseguridad para un proyecto porcino ubicado en el municipio de Ocaña, Norte de Santander. Describe las medidas de bioseguridad requeridas por el ICA como registro de entrada y salida, limpieza y desinfección, control de plagas, tratamiento de agua y residuos. También incluye un diagnóstico del proyecto, identificando sus fortalezas como ducha, lavado de botas y registros de control, y áreas que requieren mejora.
Dr. Cameron Schmitt - Talking Animal Health - PRRS: The Challenge ContinuesJohn Blue
Talking Animal Health - PRRS: The Challenge Continues - Dr. Cameron Schmitt, Pipestone Vet Clinic, from the 2013 Iowa Pork Congress, January 23-24, Des Moines, IA, USA.
More presentations at http://www.swinecast.com/2013-iowa-pork-congress
This document discusses Porcine Reproductive and Respiratory Syndrome (PRRS), including its epidemiology, vaccination strategies, and control. It begins with an outline of the presentation topics, which include the disease profile, diagnostic protocol, and prevention/control strategies. It then discusses the typical and atypical forms of PRRS, describing symptoms, transmission patterns, and field observations. The document recommends vaccination programs for naive, stable positive, and unstable positive herds. It emphasizes that vaccination, close herd management, biosecurity programs, and best management practices are required to control PRRS.
Dr. Andres Perez - PRRS Epidemiology: Best Principles of Control at a Regiona...John Blue
PRRS Epidemiology: Best Principles of Control at a Regional Level - Dr. Andres Perez, University of Minnesota, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Dr. Julie Menard - What Would Dr. Leman Do... for PRRSJohn Blue
What Would Dr. Leman Do... for PRRS - Dr. Julie Menard, F. Menard, Inc., from the 2012 Allen D. Leman Swine Conference, September 15-18, St. Paul, Minnesota, USA.
Dr. David Wright - PRRS: Understanding the Current State, Future Impact and W...John Blue
The document discusses the current situation of PRRS (Porcine Reproductive and Respiratory Syndrome) in Minnesota and nationally. It provides an update on the progress of the Minnesota N212 Regional PRRS Elimination Project, including a decrease in positive sites. Additional research findings are presented on monitoring during herd closure, impacts of PRRS vaccination methods, and transport biosecurity. Opportunities for further progress in 2014 include expanding to include PEDV and automating data collection. Continued cooperation and communication are needed to control and eliminate PRRS.
Dr. Kurt Rossow - Disease Mapping for PRRSJohn Blue
Disease Mapping for PRRS - Dr. Kurt Rossow, DVM, Veterinary Diagnostic Laboratory, University of Minnesota, from the 2013 Minnesota Pork Congress, January 16-17, Minneapolis, MN, USA.
More presentations at http://www.swinecast.com/2013-minnesota-pork-congress
This document discusses strategies for controlling PRRS (Porcine Reproductive and Respiratory Syndrome) and Aujesky's disease in swine. It emphasizes that biosecurity, control measures, and eradication efforts are needed to manage these prevalent and costly diseases. Specifically, it highlights that biosecurity is critical to prevent virus transmission between farms, control aims to minimize damage from the virus, and eradication seeks to ultimately remove the virus. It also contrasts key differences between PRRS and Aujesky's viruses and discusses vaccination and testing strategies used for eradication of Aujesky's disease.
VarSeq provides powerful annotation capabilities for variant analysis including gene tracks, assemblies, variant functions, frequency tracks, functional predictions, and transcript annotations. It integrates information from over 20 public databases and sources and updates annotations monthly to provide the most current clinically relevant information for researchers. By centralizing variant annotations from disparate sources, VarSeq saves customers significant time and resources compared to manual curation of this data.
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
In the rapidly evolving field of genomic analysis, staying current with the latest research, data sources, and test advancements is crucial. In this webinar, we review how VarSeq addresses the needs to stay on top of the latest with the release of VarSeq 2.6.0.
This release features an exome-optimized workflow for LOH and CNV calling as well as the introduction of VSPGx to produce pharmacogenomic reports for gene panels as well as exomes and genomes. With the recent release of gnomAD v4, we have had many requests for the integration of this large update to the most population frequency source. With VarSeq 2.6.0, the latest version of gnomAD has been integrated into VSClinical and the updated tracks spans beyond variants to cover CNVs and gene scores to update all your workflows to the latest data.
In this webcast, we will cover.
Improved VS-CNV performance and updated exome analysis workflows.
Pharmacogenomics in action: Utilizing VSPGx for exome and genome assessments.
gnomAD v4 in practice: Updated automated and manual variant interpretation workflows.
Join us for an insightful session on the latest VarSeq 2.6.0 features, bringing you the most up-to-date data and workflows for your genomic analysis.
Best Practices for Validating a Next-Gen Sequencing WorkflowGolden Helix
Validating an NGS workflow is an iterative process that begins with collaboration with personnel and planning protocols for the entire workflow from sample preparation, sequencing and variant calling, all the way to data analysis and reporting. At Golden Helix, while we do not provide pre-validated black-box workflows, we provide our customers with support to validate workflows in a transparent manner, and assist them in reaching production deadlines. This webcast will be led by members of our Field Application Scientist team, and we will explore some of the best practices for NGS workflow validation that we have observed and helped to implement based on real-world examples from our customer base. Key topics for discussion will include:
Sample preparation and collection of adequate case/control data
Designing a robust workflow with special considerations for single versus family analyses and phenotypic considerations
Generating the desired output for clinical or other reports
Real world NGS workflow validation strategies
Tune in for tips and strategies that you can deploy when designing and validating your NGS workflow.
This document provides information on quality control and quality assurance in medical laboratories. It defines key terms like quality control, quality assurance, and quality assessment. It describes variables that can affect result quality and sources of errors. Random errors are unpredictable variations while systematic errors create biases. The document outlines Westgard rules, which are used to evaluate analytical runs and detect random and systematic errors. Steps for resolving quality control problems and minimum criteria for determining when results are out of control are also discussed.
This document discusses RNA interference and provides information about QIAGEN's SureSilencing shRNA plasmids for gene knockdown experiments. It begins with an introduction to RNAi mechanisms and challenges. It then describes QIAGEN's SureSilencing shRNA plasmid solution, which features guaranteed high knockdown efficiency, multiple designs to control off-target effects, and experimental validation. The document reviews the plasmid features, design algorithm, applications and provides a workflow for gene knockdown experiments using the plasmids. It emphasizes the importance of including appropriate controls and validation steps to ensure successful RNAi experiments.
1. New technologies enable generating large amounts of human omics data and emerging network modeling approaches for diseases.
2. Increased computing power through cloud infrastructure allows an open and collaborative approach to solving biomedical problems.
3. A nascent movement gives patients more control over sharing private information, facilitating data sharing.
4. Open social media and gaming are being used by citizens and experts to solve problems together.
5. These trends could empower an open community of patients, researchers, and funders to accelerate biomedical research.
Annotating and Cataloging CNVs in VarSeqGolden Helix
Golden Helix offers software solutions for analyzing copy number variations (CNVs) detected from next-generation sequencing (NGS) data. Their VarSeq software uses normalization, reference samples, and probabilistic modeling to call CNVs from gene panels, exomes, and whole genomes. It flags low quality CNV calls and samples based on coverage and variability. VarSeq annotates CNVs by comparing to public databases and applying the Jaccard index metric to determine similarity between regions. Golden Helix will demonstrate VarSeq at the AMP conference in November 2018.
Pcr technology and its importance in covid 19 pandemicAnupam Maity
Since the discovery of the PCR technology, its application in the various fields is increased gradually. Based on to this principle, many variations of the PCR have been established. Year by year, it is upgraded very much. It is established as a most common and accurate technique for the detection of the various diseases in the field of medicine. Now it is a ‘Gold standard’ for the detection of covid-19 also, which is much needed to contain the spread of the virus. Though various detection techniques are there for detection, but real time RT-PCR (variation of PCR) is most reliable. Viral detection is based on a simple principle of nucleic acid (viral) amplification. Various manufacturing companies are manufacturing the PCR instrument. Though the accuracy of the instruments are slightly differ to each other.
This document discusses the area under the disease progress curve (AUDPC) method for quantifying plant disease over time. It explains that AUDPC involves discretizing time points and calculating the average disease intensity between each pair of points. The document provides an example of calculating AUDPC using 5 time points and disease percentage data. It notes that AUDPC allows comparison of varieties/treatments but not experiments. Relative AUDPC (rAUDPC) standardizes the measure and allows comparison across experiments. The conclusions state that AUDPC is useful for disease management decision making and resistance evaluation.
Bioinformatics tools for the diagnostic laboratory - T.Seemann - Antimicrobi...Torsten Seemann
Torsten Seemann discussed bioinformatic tools for diagnostic laboratories using whole genome sequencing (WGS). He explained that WGS generates large amounts of sequencing reads that can be assembled de novo or aligned to references to identify single nucleotide polymorphisms (SNPs) and characterize genomes. Key applications of WGS include diagnostic identification, antimicrobial resistance profiling, virulence factor detection, and high-resolution epidemiological typing through SNP analysis and phylogenetic trees. Seemann emphasized that WGS analysis requires metadata, domain expertise, and open data sharing for maximum public health benefit.
6-8-2015 AACC Poster HIV p24 S-PLEX - Stengelin_finalLawrence Hwang
The document describes Meso Scale Diagnostics' (MSD) development of a highly sensitive electrochemiluminescence immunoassay for detecting HIV p24 protein. Key points:
- MSD developed a next-generation p24 assay using their S-PLEX technology that is 10,000 times more sensitive than current p24 ELISAs and comparable to PCR assays.
- The assay has a detection limit of 1 fg/mL (less than 1 virus particle) and can be run on MSD's QuickPlex and SECTOR platforms without specialized equipment.
- Testing of seroconversion panels demonstrated the assay was as sensitive as PCR methods at detecting acute HIV infection between sample collection days.
This document discusses RNA interference (RNAi) techniques such as silencing RNA and CRISPR/Cas9. It explains that double-stranded RNA is cut by the enzyme Dicer into short interfering RNAs (siRNAs) that can degrade mRNA strands in a highly specific process. RNAi is involved in regulating 30% of the human genome and acts as a defense mechanism against viruses and transposons. The document also discusses selecting effective siRNAs, considerations for species variation and secondary RNA structures, and strategies for gene knockdown screening using shRNA and CRISPR/Cas9.
This document provides an overview of RNA interference (RNAi) technology and its applications in high-throughput screening. It discusses the RNAi pathway and how siRNAs can be used to silence gene expression. The document outlines some challenges of RNAi screening including off-target effects and highlights the importance of validation. It also promotes QIAGEN's siRNA design tools and libraries for optimizing RNAi experiments and minimizing false positives and negatives in high-throughput screens.
This document summarizes the work done by an intern during their summer internship in the Medical Physics Department of Radiology. The intern conducted research to predict cancer outcomes based on breast lesion features. Key work included feature extraction from mammograms, analyzing features to differentiate malignant and benign lesions using ROC analysis and LDA, and exploring features to predict invasive vs. non-invasive cancer. Top predictive features were FWHM ROI, diameter, and margin sharpness. The intern gained skills in medical image analysis, statistical analysis, and evaluating results to identify trends.
Processing Hereditary Cancer Panels in VarSeqGolden Helix
Processing variants related to cancer is an incredibly critical process and a primary goal is to not only assess the variants rapidly but also accurately. A major improvement to cancer panel workflow efficiency is to utilize VarSeq for variant filtering, annotating, and interpretation. In this webcast we’ll cover some important quality assurance capabilities VarSeq provides, multiple approaches to build targeted panels, how to access/utilize numerous cancer annotations, and finally work through the ACMG guideline process on the selected germline cancer variants. The overall goal is to cover the basics of building the cancer gene panel project template so that it can be used routinely in high throughput environments.